Αρχική World News Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic... World News Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma Από Ogkologos - 2 Ιουλίου, 2025 530 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Spending Review 2020 – Steps in the right direction, but opportunities... 25 Νοεμβρίου, 2020 Heart Problems: Investigating the Cardiac Side Effects of Cancer Treatments 21 Σεπτεμβρίου, 2018 12 myths about sun safety debunked 31 Ιουλίου, 2023 A Clinical Signal of Efficacy Observed with a Combination of Nivolumab... 20 Ιουνίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling... High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults... News digest – naked mole-rats, junk food deals, ovarian cancer drug... Opinion: ‘Medical research charities are falling through the cracks of COVID-19...